title: Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway.
abstract: Cervical cancer (CC) is a malignant neoplasm arising from cells originating in the cervix uteri, among the top causes of death from cancer in women. In a gene expression profiling study of metabolic response to treatment, PI3K/Akt signaling pathway are associated with the development of CC. A common mechanism of Akt activation seen in cancer types is alterations in the upstream regulators of Akt such as phosphatidylinositol 3-kinase (PI3K), which is overexpressed in cervical cancer tissues, and leads to phosphorylation of Akt. Both PI3K and Akt inhibitors exist and may be therapeutically valuable. In the present study, we use MTT assay and western blot for the high-throughput screening to select specific inhibitors of PI3K/Akt signaling pathway, and then obtain fucoxanthin. Fucoxanthin is a water-soluble dietary fiber, taken from the unique slimy component of alginic cells. Various studies have pointed out that fucoxanthin is very effective for the treatment of cancer. Our results have shown that fucoxanthin induced a significant apoptosis of HeLa cells, compared with other candidates. After treatment with fucoxanthin for 24 h, the level of phosphorylation was inhibited in a dose-dependent manner, and the proteins of apoptotic markers were changed in HeLa cells. And fucoxanthin could suppress tumor growth in vivo. In addition, the mitochondrial signal transduction pathway maybe was involved in its mechanism and NF-κB activation was decreased after treatment with fucoxanthin. Therefore, fucoxanthin may be used as anti-cervical cancer drugs in the future.
authors.affiliation: Department of Obstetrics and Gynecology, Provincial Hospital, Affiliated to Anhui Medical University, Hefei, 230001, China.
authors.forename: Guoliu
authors.initials: G
authors.lastname: Ye
authors.forename: Qin
authors.initials: Q
authors.lastname: Lu
authors.forename: Weidong
authors.initials: W
authors.lastname: Zhao
authors.forename: Danli
authors.initials: D
authors.lastname: Du
authors.forename: Lijie
authors.initials: L
authors.lastname: Jin
authors.forename: Yusheng
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D005434:Flow Cytometry; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016328:NF-kappa B / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D058539:Phosphatidylinositol 3-Kinase / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D024341:Xanthophylls / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D016328:NF-kappa B; D024341:Xanthophylls; C025164:fucoxanthin; D000255:Adenosine Triphosphate; D058539:Phosphatidylinositol 3-Kinase; D051057:Proto-Oncogene Proteins c-akt
references.citation: Bull Cancer. 2012 Feb 1;99(2):173-80
references.pmid: 21742593
references.citation: Breast Cancer Res Treat. 2013 Apr;138(2):369-81
references.pmid: 23430223
references.citation: Int J Biol Sci. 2012;8(5):650-62
references.pmid: 22606046
references.citation: Gynecol Oncol. 2012 Aug;126(2):291-303
references.pmid: 22504292
references.citation: Anticancer Drugs. 2005 Sep;16(8):797-803
references.pmid: 16096426
references.citation: Head Neck. 2012 Jan;34(1):10-4
references.pmid: 21438064
references.citation: Eur J Pharmacol. 2010 Dec 15;649(1-3):369-75
references.pmid: 20868674
references.citation: Clin Cancer Res. 2006 Jan 1;12(1):250-6
references.pmid: 16397049
references.citation: Biochim Biophys Acta. 2004 Nov 18;1675(1-3):113-9
references.pmid: 15535974
references.citation: Biochem Pharmacol. 2006 Oct 30;72(9):1054-68
references.pmid: 16973133
references.citation: Mol Cell Biochem. 2013 Jul;379(1-2):7-18
references.pmid: 23543150
references.citation: Leukemia. 2003 Mar;17(3):590-603
references.pmid: 12646949
references.citation: Cancer Lett. 2004 Apr 8;206(2):193-9
references.pmid: 15013524
references.citation: Semin Cancer Biol. 2003 Apr;13(2):107-14
references.pmid: 12654254
references.citation: Molecules. 2012 Aug 24;17(9):10052-64
references.pmid: 22922276
references.citation: Mol Cancer. 2011 Apr 15;10:39
references.pmid: 21496227
references.citation: Oncol Lett. 2010 Jan;1(1):3-11
references.pmid: 22966247
references.citation: Diabetologia. 2009 Jan;52(1):125-35
references.pmid: 18949453
references.citation: Int J Mol Sci. 2011;12(7):4722-34
references.pmid: 21845107
references.citation: Clin Cancer Res. 2012 Mar 1;18(5):1464-71
references.pmid: 22235101
references.citation: Clin Cancer Res. 2009 Oct 15;15(20):6421-9
references.pmid: 19825959
references.citation: Environ Toxicol Pharmacol. 2013 Jan;35(1):39-46
references.pmid: 23228706
references.citation: Int J Mol Med. 2006 Jul;18(1):147-52
references.pmid: 16786166
references.citation: Anticancer Res. 2012 Mar;32(3):807-13
references.pmid: 22399598
references.citation: Int J Cancer. 2012 Nov 15;131(10):2349-59
references.pmid: 22323075
references.citation: Biochim Biophys Acta. 2005 Nov 30;1726(3):328-35
references.pmid: 16236452
references.citation: Cancer Res. 2012 Oct 1;72(19):5048-59
references.pmid: 22875023
references.citation: Methods Mol Biol. 2009;512:169-207
references.pmid: 19347278
references.citation: Onco Targets Ther. 2012;5:315-28
references.pmid: 23144564
references.citation: Int J Oncol. 2013 Mar;42(3):921-8
references.pmid: 23314408
references.citation: Cancer Discov. 2012 Mar;2(3):248-59
references.pmid: 22585995
references.citation: Mar Drugs. 2012 Oct;10(10):2337-48
references.pmid: 23170088
references.citation: Biosci Biotechnol Biochem. 1999 Mar;63(3):605-7
references.pmid: 10227153
references.citation: Anticancer Agents Med Chem. 2013 Sep;13(7):1014-24
references.pmid: 23272911
references.citation: Biochem J. 2014 May 15;460(1):117-25
references.pmid: 24593661
references.citation: Chin J Cancer. 2013 Jul;32(7):376-9
references.pmid: 23668928
references.citation: Int J Gynecol Cancer. 2012 May;22(4):623-9
references.pmid: 22343974
references.citation: Clin Exp Metastasis. 1989 Jan-Feb;7(1):117-25
references.pmid: 2908826
references.citation: Anticancer Res. 2007 Sep-Oct;27(5A):3035-44
references.pmid: 17970042
references.citation: Diabetes. 2001 May;50(5):1047-55
references.pmid: 11334407